The FDA has lifted one of the two clinical holds placed on Kezar Life Sciences’ zetomipzomib, leading the biotech to speculate on whether to reignite another program for the same drug that remains ...

Earlier use of combination therapies is purported to improve outcomes in many disease states, including lupus nephritis.